Control of progesterone and inhibin secretion during the luteal phase in the macaque.
We investigated the temporal relationship between serum concentrations of progesterone and immunoreactive inhibin after treatment with an LHRH antagonist ([N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Trp3,D-hArg(Et2)6,D-Ala10++ +] -LHRH), during the mid-luteal phase in the macaque. Further, in an attempt to obtain a model of transitory suppression of luteal function, the effect of treatment with the LHRH antagonist for 1, 2 or 3 days during the mid-luteal phase on serum concentrations of progesterone and immunoreactive inhibin was compared. Differences in the pattern of decline of the two hormones were observed. Progesterone concentrations fell by 6 h after antagonist administration while inhibin was not significantly suppressed until 48 h. Treatment with three injections of LHRH antagonist caused a sustained suppression of luteal function as shown by low serum concentrations of progesterone and inhibin. Recovery of progesterone and inhibin secretion was observed in two out of six macaques treated with two injections of antagonist and in three out of six treated with a single injection. Therefore, with the regimens of LHRH antagonist which we employed this approach was not conducive to obtaining a reliable transitory suppression of luteal function. To elucidate further the gonadotrophin control of inhibin, six macaques were treated with three injections of the LHRH antagonist to induce a permanent suppression of luteal function but received concomitantly either human chorionic gonadotrophin (hCG) or human FSH daily for 5 days (n = 3 per group). FSH failed to prevent the antagonist-induced fall in progesterone and inhibin while hCG treatment completely reversed the inhibitory effects of the LHRH antagonist.(ABSTRACT TRUNCATED AT 250 WORDS)
Smith
K B
KB
MRC Reproductive Biology Unit, Centre for Reproductive Biology, Edinburgh.
Fraser
H M
HM
D000818:Animals; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D002940:Circadian Rhythm / Q000187:drug effects; D003338:Corpus Luteum / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D007265:Inhibins / Q000097:blood / Q000378:metabolism*; D008183:Luteal Phase / Q000502:physiology*; D008251:Macaca; D011374:Progesterone / Q000097:blood / Q000378:metabolism*
D006063:Chorionic Gonadotropin; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D007265:Inhibins; C060521:LHRH, N-Ac-naphthyl(1)-(4-Cl-Phe)(2)-Trp(3)-Arg(6)-Ala(10)-; D005640:Follicle Stimulating Hormone